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the progression of renal dysfunction even after adjusting for
other clinical risk factors, including hypertension, urinary pro-
tein excretion of more than 1.0 g/day, and no administration
of renin angiotensin system inhibitors. This study supports the
role of MUC20 in regulating the Met signaling cascade, which is
implicated not only in renal development and maintenance of
kidney functions but also in tubular repair and regeneration un-
der pathological conditions in human glomerulonephritis. The
tandem repeat polymorphism in MUC20, which may directly
affect its oligomerization and binding to Met, is associated with
the renal prognosis of IgAN. Factors that regulate the function
of MUC20 may be useful therapeutic agents for progression of
renal injury.
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The use of animal organs for human transplantation could
potentially alleviate the worldwide critical shortage of donor
organs, and thus has stimulated investigation of novel strate-
gies directed at making xenotransplantation applicable to the
clinic. The latter will likely require overcoming barriers of rejec-
tion through strategies utilizing either immune suppression or
tolerance induction, or a combination of the two. We have pre-
viously reported that vascularized donor thymic tissue grafts,
transplanted either as composite thymokidneys or vascularized
thymic lobe grafts, induced tolerance across fully allogeneic bar-
riers in miniature swine. Recently, we have applied the strat-
egy of vascularized thymic lobe transplantation in a model of
hDAF pig-to-baboon xenotransplantation and demonstrated
that these grafts induced donor-specific unresponsiveness for
up to 2 to 3 months following transplantation, at which time the
grafts were lost from apparent humoral rejection. We have now
extended these studies using cloned a-1,3-galactosyltransferase
(GalT) knockout pigs as donors. We report here our initial ex-
perience in a preclinical model of pig-to-baboon xenotrans-
plantation. This abstract presents clinical data on recipients
of GalT knockout kidneys, especially focusing on four long-
term recipients of GalT knockout kidney plus thymus trans-
plantation in detail. Briefly, these four baboons receiving either
xeno-thymokidneys or vascularized thymic lobe plus kidney
maintained longer than 2 months. Three of four long-term sur-
vivors maintained normal plasma creatinine levels for 56, 68,
and 83 days, respectively, before expiring from unexpected
causes (anesthetic complication during surgery to replace an
infected intravenous catheter (day 68), and myocardial infarc-
tion, possibly drug-induced on days 56 and an arterial catheter
trouble on day 83. Cytotoxic T-lymphocyte assays on day 78
in one long-term acceptor showed that the baboon maintained
anti-allo cytotoxic T-lymphocyte responses but lost antipig cyc-
totoxic T-lymphocyte responses, indicating donor-specific un-
responsiveness. The fourth baboon experienced an apparent
rejection crisis between days 53 and 65, which reversed with
anti-T-cell rejection therapy; subsequently the animal expired
on day 81 from pneumonia. Neither hyperacute nor acceler-
ated acute rejection was observed in any animal. Use of GalT
knockout donors markedly extends the survival of vascularized
thymus plus renal xenografts in baboons. Although the induc-
tion regimen still needs to be modified to reduce complications,
these initial results are encouraging with regard to the poten-
tial of cotransplanting vascularized thymic tissue with organ
xenografts as a means of achieving long-term tolerance across
pig-to-primate barriers.
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The introduction of cyclosporine (CsA) into clinical practice
has resulted in marked improvement in the short-term outcome
of organ transplantation, and 1-year survival of renal allografts
has improved significantly. However, the annual rate of kidney
graft loss caused by chronic allograft nephropathy (CAN) has
remained stable over last decade. CAN may result from peri-
operative ischemia at the time of transplantation. Furthermore,
chronic CsA nephrotoxicity may progress to an irreversible re-
nal lesion characterized by tubular atrophy, striped interstitial
fibrosis, hyalinosis of the afferent arteriole, and progressive re-
nal impairment. Recent report demonstrated the therapeutic
effects of hepatocyte growth factor (HGF) in preventing CAN
using a well-established rat CAN model. They showed that
HGF treatment during the initial 4 weeks after engraftment
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prevented onset of CAN and associated death and provided
longlasting benefit in terms of graft survival. Exogenous HGF is
very unstable in the blood circulation due to the rapid clearance
by the liver. To circumvent this problem, we developed a new
gene transfer system by electroporation in vivo. Therefore, this
gene transfer approach represents a useful technique to inves-
tigate the therapeutic potential of HGF gene transfer for long-
term survival of kidney allograft. The goal of the present study
was to assess the renoprotective potential and safety of HGF
gene transfer using a porcine kidney transplant warm ischemia
injury model or CsA nephrotoxicity model. In the first set of ex-
periments, following left porcine kidney removal, 10 minutes of
warm ischemic injury was intentionally induced. Next, the HGF
expression vector or vehicle was infused into the renal artery
with the renal vein clamped ex vivo, and electric pulses were dis-
charged using bathtub-type electrodes. Kidney grafts were then
transplanted after removing the right kidney. Histopathologic
examination of vehicle-transfected kidney transplant revealed
initial tubular injury followed by tubulointerstitial fibrosis. In
contrast, HGF-transfected kidneys showed no initial tubular
damage and no interstitial fibrosis at 6 months posttransplant.
In the next set of experiments, CsA was subcutaneously admin-
istered daily under low sodium diet, and HGF gene was trans-
ferred into skeletal muscle by electroporation on days 7 and 14.
We also examined the antiapoptotic mechanism of HGF using
human proximal tubular epithelial cells. HGF gene transfer res-
cued CsA-induced initial tubular injury, and suppressed intersti-
tial infiltration of endothelium-1 (ED-1)–positive macrophages
in CsA nephrotoxicity. In addition, HGF significantly inhibited
tubular cell apoptosis, and increased the number of proliferat-
ing tubular epithelial cells. In vitro studies suggest that HGF
executes the antiapoptotic function by enhancing the phospho-
rylation of Akt and Bcl-2. Northern blot analysis demonstrated
that HGF gene transfer suppressed cortical mRNA levels of
transforming growth factor-b (TGF-b). Consequently, HGF
gene transfer significantly reduced a striped interstitial pheno-
typic alteration and fibrosis. We conclude that electroporation-
mediated HGF gene transfection protects the kidney against
graft injury.
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For those with uremia, renal function is presently replaced by
dialysis or allotransplantation. Neither approach is ideal phys-
iologically and allotransplantation suffers from limited avail-
ability of donors. In the future, the need to replace or amplify
renal function may increase dramatically as molecular diagnosis
identifies those at risk for cancer and renal failure, and as small
impairments of renal function are found to increase cardiovas-
cular risk. The heightened demand for renal replacement may
be met by the development or advancement of technologies, in-
cluding stem cells, cloning, organogenesis, and xenotransplan-
tation. The ideal replacement of renal function, however, may
not be achieved by any one of the technologies, but rather by a
combination. Cloning, stem cells, organogenesis and xenotrans-
plantation can potentially be combined for replacement of re-
nal function. New technologies or combinations of technologies
for replacement or regeneration of renal function share certain
challenges. One challenge is the need to generate organs or
organ-like structures that exhibit adequate function. Another
challenge is that the achieving of adequate size engenders some
risk of tumor formation. Still another challenge stems from the
controversy regarding the capacity of stem cells to differentiate
or transdifferentiate and the possibility that fusion of stem cells
or their progeny with differentiated cells may contribute to re-
generation and histogenesis. The implications of cell fusion in
such systems were discussed.
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